Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Mainz Biomed appoints Darin Leigh as chief commercial officer » 05:20
04/26/22
04/26
05:20
04/26/22
05:20
MYNZ

Mainz Biomed

$13.25 /

+0.45 (+3.52%)

Mainz Biomed announced…

Mainz Biomed announced the appointment of Darin Leigh as chief commercial officer. Darin comes to the role with over 25 years of product lifecycle management and global commercial operations experience across Europe, the United States and Asia. More recently, as chief commercial officer at emergency medical services company CDR Health, Darin was part of the commercial team that delivered millions of dollars in new contracts as CDR scaled testing, vaccination and monoclonal antibody treatment services in response to the Covid-19 pandemic for the state of Florida.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$13.25 /

+0.45 (+3.52%)

  • 26
    Jan
  • 04
    Nov
MYNZ Mainz Biomed
$13.25 /

+0.45 (+3.52%)

Hot Stocks
Mainz Biomed completes ColoAlert pre-submission process with FDA » 05:24
03/31/22
03/31
05:24
03/31/22
05:24
MYNZ

Mainz Biomed

$15.30 /

+0.24 (+1.59%)

Mainz Biomed announced…

Mainz Biomed announced that it has received supportive feedback from the FDA on the company's pre-submission package profiling the potential pivotal clinical trial design for ColoAlert, its detection test for colorectal cancer, or CRC. As Mainz prepares to launch ColoAlert's pivotal clinical trial, the company also announced the formal commencement of its reimbursement process for ColoAlert by scheduling an initial meeting with The Centers for Medicare and Medicaid Services, or CMS, in April. The CMS is a federal agency in the U.S. Department of Health and Human Services, or HHS, that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children's Health Insurance Program and health insurance portability standards.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$15.30 /

+0.24 (+1.59%)

  • 26
    Jan
  • 04
    Nov
MYNZ Mainz Biomed
$15.30 /

+0.24 (+1.59%)

Hot Stocks
Mainz Biomed partners with Sentinel Diagnostics, Alcedis for ColoFuture study » 05:11
03/17/22
03/17
05:11
03/17/22
05:11
MYNZ

Mainz Biomed

$14.30 /

+0.88 (+6.56%)

Mainz Biomed announced…

Mainz Biomed announced partnerships with Sentinel Diagnostics and Alcedis GmbH to support ColoFuture, its clinical study evaluating the potential to integrate a portfolio of novel mRNA biomarkers into ColoAlert, the company's highly efficacious, and easy-to-use detection test for colorectal cancer, or CRC. Under the terms of the partnership, Mainz will have access to the SENTiFIT 270 Analyzer, Sentinel's automated Fecal Immunochemical Test, or FIT, processing system for the ColoFuture study. An essential component of ColoAlert is the utilization of a FIT which provides a complete review of blood in the stool, a condition often associated with cancerous polyps and colorectal carcinoma. It is the combination of ColoAlert and FIT results that provide the diagnostic outcome. This partnership enables Mainz to transition from deploying a manual FIT processing methodology to an automated system for potential future use in the EU commercial setting and in the company's forthcoming U.S. clinical trial. In addition to the Sentinel appointment, Mainz is pleased to partner with Alcedis, a full-service contract research organization providing clinical trial management for biotechnology and medical device companies across the globe. Under the terms of the engagement, Alcedis will provide Mainz with the full range of services and responsibilities associated with executing ColoFuture, including patient recruitment, overseeing study protocol compliance, and the documentation and reporting of patient results.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$14.30 /

+0.88 (+6.56%)

  • 26
    Jan
  • 04
    Nov
MYNZ Mainz Biomed
$14.30 /

+0.88 (+6.56%)

Over a quarter ago
Hot Stocks
Mainz Biomed provides regulatory update on ColoAlert » 05:06
02/23/22
02/23
05:06
02/23/22
05:06
MYNZ

Mainz Biomed

$13.71 /

-2.32 (-14.47%)

Mainz Biomed announced…

Mainz Biomed announced that its pre-submission filed with the FDA for ColoAlert has been accepted for review. By accepting the pre-submission for review, the FDA will provide feedback to the company on its proposed pivotal U.S. clinical trial design for ColoAlert, its detection test for colorectal cancer. The FDA feedback is expected in calendar Q2, and will offer Mainz the opportunity to gain preliminary insight and guidance on the potential technical parameters and endpoints of the study, which is on track to commence in 2023.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$13.71 /

-2.32 (-14.47%)

  • 26
    Jan
  • 04
    Nov
MYNZ Mainz Biomed
$13.71 /

-2.32 (-14.47%)

Hot Stocks
Mainz Biomed announces ColoAlert partnership with Laboratory Monchengladbach » 05:13
02/14/22
02/14
05:13
02/14/22
05:13
MYNZ

Mainz Biomed

$15.03 /

+0.45 (+3.09%)

Mainz Biomed announced a…

Mainz Biomed announced a partnership with Labor MVZ Dr. Stein + Kollegen, or Laboratory Monchengladbach. Laboratory Monchengladbach, one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany, will commercialize ColoAlert, Mainz Biomed's detection test for colorectal cancer, ot CRC. With a team of over 500 employees that includes biologists, chemists, doctors and other specialists, Laboratory Monchengladbach services over 2500 physicians, processing over 5M samples in total annually and screening approximately 1000 patients per week specifically for CRC. Under the terms of the partnership, Mainz Biomed will co-brand ColoAlert with Laboratory Monchengladbach, and sell its polymerase chain reaction, or PCR, assay kits for advanced colorectal cancer detection, on an on-demand basis for use by Labor Monchengladbach's network of physicians and their patients. In order to optimize awareness and adoption, Mainz Biomed and Labor Monchengladbach will also collaborate to deliver a comprehensive marketing and education campaign to include direct-to-consumer advertising, cross channel promotion to physician networks, webinars and sales representative training.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$15.03 /

+0.45 (+3.09%)

  • 26
    Jan
  • 04
    Nov
MYNZ Mainz Biomed
$15.03 /

+0.45 (+3.09%)

Hot Stocks
Mainz Biomed commences ColoFuture study » 05:13
02/04/22
02/04
05:13
02/04/22
05:13
MYNZ

Mainz Biomed

$12.95 /

-1.15 (-8.16%)

Mainz Biomed announced it…

Mainz Biomed announced it has commenced ColoFuture, an international clinical study to evaluate the potential to integrate a portfolio of novel mRNA biomarkers into ColoAlert, the company's highly efficacious, and easy-to-use detection test for colorectal cancer which is being commercialized across Europe. The ColoFuture study will evaluate the effectiveness of these biomarkers to enhance ColoAlert's technical profile to extend its capability to include the identification of advanced adenomas, a type of pre-cancerous polyp often attributed to CRC, while increasing ColoAlert's rates of diagnostic sensitivity and specificity.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$12.95 /

-1.15 (-8.16%)

  • 26
    Jan
  • 04
    Nov
MYNZ Mainz Biomed
$12.95 /

-1.15 (-8.16%)

On The Fly
Fly Intel: Pre-market Movers » 09:01
01/26/22
01/26
09:01
01/26/22
09:01
T

AT&T

$26.47 /

+0.13 (+0.49%)

, GLW

Corning

$35.29 /

-0.02 (-0.06%)

, MSFT

Microsoft

$289.02 /

-7.72 (-2.60%)

, ABT

Abbott

$123.12 /

-0.54 (-0.44%)

, KMB

Kimberly-Clark

$139.56 /

-2.245 (-1.58%)

, GATO

Gatos Silver

$10.19 /

+0.145 (+1.44%)

, MYNZ

Mainz Biomed

$20.32 /

-1.03 (-4.82%)

, NRXP

NRx Pharmaceuticals

$3.18 /

+0.005 (+0.16%)

, JKS

JinkoSolar

$41.04 /

-0.145 (-0.35%)

, CLNE

Clean Energy

$5.51 /

+0.26 (+4.95%)

, BA

Boeing

$204.00 /

-0.34 (-0.17%)

Check out this morning's…

ShowHide Related Items >><<
T AT&T
$26.47 /

+0.13 (+0.49%)

NRXP NRx Pharmaceuticals
$3.18 /

+0.005 (+0.16%)

MYNZ Mainz Biomed
$20.32 /

-1.03 (-4.82%)

MSFT Microsoft
$289.02 /

-7.72 (-2.60%)

KMB Kimberly-Clark
$139.56 /

-2.245 (-1.58%)

JKS JinkoSolar
$41.04 /

-0.145 (-0.35%)

GLW Corning
$35.29 /

-0.02 (-0.06%)

GATO Gatos Silver
$10.19 /

+0.145 (+1.44%)

CLNE Clean Energy
$5.51 /

+0.26 (+4.95%)

BA Boeing
$204.00 /

-0.34 (-0.17%)

ABT Abbott
$123.12 /

-0.54 (-0.44%)

T AT&T
$26.47 /

+0.13 (+0.49%)

01/20/22 Tigress Financial
AT&T price target raised to $41 from $36 at Tigress Financial
01/11/22 Citi
Citi adds Crown Castle, Switch to 'Positive Catalyst Watch List'
01/11/22 Citi
Citi adds AT&T to 'positive catalyst watch list,' keeps $29 target
01/07/22 Wells Fargo
Wells upgrades AT&T to neutral with downside risks 'more limited'
GLW Corning
$35.29 /

-0.02 (-0.06%)

01/25/22 BofA
Corning price target lowered to $45 from $48 at BofA
01/13/22 Deutsche Bank
Deutsche Bank cuts Corning, says near-term estimates face downward reset
01/13/22 Deutsche Bank
Corning downgraded to Hold from Buy at Deutsche Bank
12/21/21 Deutsche Bank
Corning price target lowered to $41 from $43 at Deutsche Bank
MSFT Microsoft
$289.02 /

-7.72 (-2.60%)

01/26/22 Morgan Stanley
Microsoft price target raised to $372 from $364 at Morgan Stanley
01/26/22 Oppenheimer
Microsoft price target raised to $340 from $330 at Oppenheimer
01/26/22 Stifel
Initial Azure 'noise' in Q2 quickly allayed by Microsoft guidance, says Stifel
01/26/22 Wedbush
Wedbush remains bullish on Microsoft after results as cloud growth not slowing
ABT Abbott
$123.12 /

-0.54 (-0.44%)

01/25/22 Piper Sandler
DexCom shared continue to offer great entry point, says Piper Sandler
01/19/22 Wells Fargo
Wells Fargo upgrades DexCom to Overweight with $575 price target
01/10/22 Cowen
Abbott price target raised to $150 from $140 at Cowen
01/03/22 JPMorgan
JPMorgan says own these medical device stocks into next week's conference
KMB Kimberly-Clark
$139.56 /

-2.245 (-1.58%)

01/13/22 JPMorgan
Kimberly-Clark price target raised to $127 from $122 at JPMorgan
01/11/22 Exane BNP Paribas
Kimberly-Clark downgraded to Neutral from Outperform at Exane BNP Paribas
12/17/21 JPMorgan
JPMorgan announces top 2022 stock picks in beverages, personal care
10/26/21
Fly Intel: Top five analyst downgrades
GATO Gatos Silver
$10.19 /

+0.145 (+1.44%)

01/26/22 CIBC
Gatos Silver downgraded to Neutral from Outperformer at CIBC
01/26/22 RBC Capital
Gatos Silver double-downgraded to Underperform from Outperform at RBC Capital
01/26/22 RBC Capital
Gatos Silver downgraded to Underperform from Outperform at RBC Capital
10/19/21 Goldman Sachs
Gatos Silver initiated with a Neutral at Goldman Sachs
MYNZ Mainz Biomed
$20.32 /

-1.03 (-4.82%)

NRXP NRx Pharmaceuticals
$3.18 /

+0.005 (+0.16%)

JKS JinkoSolar
$41.04 /

-0.145 (-0.35%)

01/14/22 GLJ Research
GLJ Research says 'likely a great time to aggressively short' JinkoSolar
01/11/22 GLJ Research
Solar bulls 'could be disappointed' about CPUC this week, says GLJ Research
12/02/21 GLJ Research
JinkoSolar shares have downside risk on near-term catalysts, says GLJ
12/02/21 CICC
JinkoSolar upgraded to Outperform from Market Perform at CICC
CLNE Clean Energy
$5.51 /

+0.26 (+4.95%)

01/04/22 Raymond James
Clean Energy upgraded to Market Perform from Underperform at Raymond James
01/04/22 Raymond James
Clean Energy upgraded to Market Perform from Underperform at Raymond James
07/14/21 Evercore ISI
Clean Energy initiated with an Underperform at Evercore ISI
05/11/21 Needham
Clean Energy initiated with a Buy at Needham
BA Boeing
$204.00 /

-0.34 (-0.17%)

01/20/22 Citi
Boeing price target lowered to $238 from $240 at Citi
01/18/22 Cowen
Boeing price target raised to $265 from $250 at Cowen
01/12/22 Morgan Stanley
News of 737 MAX flight in China a positive for Boeing, says Morgan Stanley
01/06/22 Susquehanna
Boeing MAX order starts year off right, says Susquehanna
T AT&T
$26.47 /

+0.13 (+0.49%)

MSFT Microsoft
$289.02 /

-7.72 (-2.60%)

KMB Kimberly-Clark
$139.56 /

-2.245 (-1.58%)

JKS JinkoSolar
$41.04 /

-0.145 (-0.35%)

GLW Corning
$35.29 /

-0.02 (-0.06%)

GATO Gatos Silver
$10.19 /

+0.145 (+1.44%)

CLNE Clean Energy
$5.51 /

+0.26 (+4.95%)

BA Boeing
$204.00 /

-0.34 (-0.17%)

ABT Abbott
$123.12 /

-0.54 (-0.44%)

  • 26
    Jan
  • 04
    Nov
  • 15
    Jul
T AT&T
$26.47 /

+0.13 (+0.49%)

MSFT Microsoft
$289.02 /

-7.72 (-2.60%)

JKS JinkoSolar
$41.04 /

-0.145 (-0.35%)

BA Boeing
$204.00 /

-0.34 (-0.17%)

ABT Abbott
$123.12 /

-0.54 (-0.44%)

T AT&T
$26.47 /

+0.13 (+0.49%)

NRXP NRx Pharmaceuticals
$3.18 /

+0.005 (+0.16%)

MYNZ Mainz Biomed
$20.32 /

-1.03 (-4.82%)

MSFT Microsoft
$289.02 /

-7.72 (-2.60%)

KMB Kimberly-Clark
$139.56 /

-2.245 (-1.58%)

JKS JinkoSolar
$41.04 /

-0.145 (-0.35%)

GLW Corning
$35.29 /

-0.02 (-0.06%)

GATO Gatos Silver
$10.19 /

+0.145 (+1.44%)

CLNE Clean Energy
$5.51 /

+0.26 (+4.95%)

BA Boeing
$204.00 /

-0.34 (-0.17%)

ABT Abbott
$123.12 /

-0.54 (-0.44%)

T AT&T
$26.47 /

+0.13 (+0.49%)

NRXP NRx Pharmaceuticals
$3.18 /

+0.005 (+0.16%)

MSFT Microsoft
$289.02 /

-7.72 (-2.60%)

KMB Kimberly-Clark
$139.56 /

-2.245 (-1.58%)

JKS JinkoSolar
$41.04 /

-0.145 (-0.35%)

GLW Corning
$35.29 /

-0.02 (-0.06%)

GATO Gatos Silver
$10.19 /

+0.145 (+1.44%)

CLNE Clean Energy
$5.51 /

+0.26 (+4.95%)

BA Boeing
$204.00 /

-0.34 (-0.17%)

ABT Abbott
$123.12 /

-0.54 (-0.44%)

Syndicate
Mainz Biomed 1.5M share Secondary priced at $15.00 » 20:36
01/25/22
01/25
20:36
01/25/22
20:36
MYNZ

Mainz Biomed

$20.32 /

-1.03 (-4.82%)

The deal priced below…

The deal priced below last closing price of $20.25. Boustead is acting as sole book running manager for the offering.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$20.32 /

-1.03 (-4.82%)

  • 26
    Jan
  • 04
    Nov
MYNZ Mainz Biomed
$20.32 /

-1.03 (-4.82%)

Syndicate
Mainz Biomed files to sell 1.5M shares of common stock » 06:25
01/24/22
01/24
06:25
01/24/22
06:25
MYNZ

Mainz Biomed

$27.61 /

+4.09 (+17.39%)

Boustead Securities is…

Boustead Securities is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$27.61 /

+4.09 (+17.39%)

  • 04
    Nov
MYNZ Mainz Biomed
$27.61 /

+4.09 (+17.39%)

Hot Stocks
Mainz Biomed engages DCN Dx to potentially integrate biomarkers into ColoAlert » 05:16
01/19/22
01/19
05:16
01/19/22
05:16
MYNZ

Mainz Biomed

$26.61 /

+5.81 (+27.93%)

Mainz Biomed announced it…

Mainz Biomed announced it has formally contracted with DCN Dx, an international developer of point-of-care diagnostics, and provider of product development services. Emily Friedland, VP of clinical research at DCN Dx will spearhead the preparation and initiation of Mainz's European centric clinical study to evaluate the potential to integrate a portfolio of recently acquired novel mRNA biomarkers into ColoAlert, the company's detection test for colorectal cancer. This suite of biomarkers which were in-licensed from Socpra Sciences Sante Et Humaines S.E.C. in early January, have demonstrated the ability to detect pre-cancerous lesions including advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer. The study is on track to commence in the first half of 2022. Under the terms of the engagement, DCN Dx will be responsible for the selection of additional clinical research organizations and assist Mainz's management with the development of robust study protocols and associated clinical processes.

ShowHide Related Items >><<
MYNZ Mainz Biomed
$26.61 /

+5.81 (+27.93%)

  • 04
    Nov
MYNZ Mainz Biomed
$26.61 /

+5.81 (+27.93%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.